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Abstract Data from a number of model systems upport a role 
for proteolysis in apoptotic cell death. Using immature rat thy- 
mocytes, we demonstrate that the inhibitors N-tosyl-L-lysyl chlo- 
romethylketone (TLCK) and N-tosyl-L-phenylalanyl chlorometh- 
ylketone (TPCK) have very different effects on apoptosis. TLCK 
inhibits apoptosis induced by diverse stimuli at an early stage 
prior to both DNA fragmentation and cytoplasmic hanges. We 
show that the TLCK-sensitive target is pre-existing and not syn- 
thesized in response to apoptotic stimuli. The contrasting effects 
of TLCK and TPCK support the hypothesis that the TLCK 
target is a trypsin-like protease which is a common effector of 
thymocyte apoptosis. 
Key words: Thymocyte apoptosis; Protease inhibitor; 
Trypsin-like protease 
I. Introduction 
Apoptosis is a major mechanism of cell death of vital impor- 
tance for normal development and tissue homeostasis [1]. Thy- 
mocyte apoptosis i  one of the best characterised xperimental 
models of apoptosis [2,3]. During apoptosis there are dramatic 
morphological nd biochemical changes in the cytoplasm and 
nucleus of a dying cell. The chromatin condenses with an atten- 
dant cleavage of DNA [1 3], initially to 200 300 and 30-50 
kilobasepair size fragments [4~7], which are then further de- 
graded to produce oligonucleosomes and the typical DNA lad- 
der pattern [3,6,7]. Cytoplasmic changes of apoptosis are char- 
acterized by dilatation of the endoplasmic reticulum [1], cell 
shrinkage [1,8,9] and alterations inmembrane permeability [10]. 
Recently, protein degradation has also been implicated in 
apoptosis in both invertebrates and mammals. In the nema- 
tode, Caenorhabditis elegans, the gene ced-3 is essential for 
apoptosis and encodes a protein similar to the mammalian 
protease, interleukin-lfl-converting e zyme (ICE) [11]. In rat 
fibroblasts, over expression of ced-3, ICE or the related nedd-2 
results in apoptosis [12,13]. In thymocytes, inhibitors of prote- 
olysis prevent internucleosomal DNA cleavage [14] and a role 
for serine and cysteine proteases has been proposed [15,16]. 
Proteolysis is also seen during apoptosis in HL-60 cells [17], 
T-cell receptor mediated cell death [18], natural killer cell killing 
[19] and TNF mediated cytotoxicity [20]. 
The aim of the present study was to determine the role of 
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proteolysis in the sequence of events leading to apoptosis in 
thymocytes. Apoptosis was induced by agents acting by differ- 
ent mechanisms, i.e. dexamethasone, a glucocorticoid [3], eto- 
poside, a DNA topoisomerase II inhibitor [4,21], stauro- 
sporine, a protein kinase inhibitor [22 ] and thapsigargin, an 
inhibitor of endoplasmic reticular Ca2+-ATPase [23]. In order 
to ascertain at what stage of the apoptotic process the inhibitors 
were acting, several techniques were used to assess apoptosis 
or properties associated with apoptotic ells. Nuclear changes 
of apoptosis were assessed by field inversion and conventional 
gel electrophoresis to detect formation of large kilobase pair 
fragments and internucleosomal cleavage of DNA respectively 
and DNA fragmentation was quantified by the diphenylamine 
method [3]. Cytoplasmic changes were assessed both by Coulter 
analysis to detect cell shrinkage and also by a flow cytometric 
method, which separates and quantifies normal and apoptotic 
cells based on changes in cell size and membrane permeability 
[10,24]. We have used two protease inhibitors, N-tosyl-c-lysyl- 
chloromethylketone (TLCK) and N-tosyl-n-phenylalanyl-chlo- 
romethylketone (TPCK), which prevent internucleosomal 
cleavage of DNA in both thymocytes and a tumour cell line 
[14,15,17]. Both TLCK and TPCK inhibit some cysteine and 
serine proteases [25]. However, TLCK irreversibly inhibits 
trypsin-like proteases, which require a basic amino acid in the 
P1 position (Schecter and Berger nomenclature), while TPCK 
irreversibly inhibits chymotrypsin-like proteases, which require 
an aromatic amino acid in the P1 position [25]. 
Our results demonstrate hat more than one protease is re- 
quired for apoptotic ell death. A TPCK-sensitive protease is 
required for internucleosomal cleavage. A pre-existing TLCK- 
sensitive protease is a common effector of early apoptotic 
changes induced by diverse stimuli. 
2. Materials and methods 
2.1. Materials 
All media and serum were from Gibco (Paisley, UK). Pronase, 
TLCK and TPCK were from Boehringer Mannheim (Mannheim, Ger- 
many). All other chemicals were from Sigma Chemical Company 
(Poole, UK). 
2.2. Preparation and incubation of thymocyte suspensions 
Suspensions of thymocytes from immature male F344 rats (4-5 
weeks old, 65 85 g) were prepared as described previously [26]. To 
induce apoptosis, thymocytes (2x 107 cells-ml ~) were incubated at 
37°C for 4 h in RPMI 1640 medium supplemented with 10% foetal 
bovine serum with either dexamethasone (0.1/~M), etoposide (10/IM), 
staurosporine (1 /.tM) or thapsigargin (0.05 /IM). Thymocytes were 
either preincubated with TLCK for 1 h prior to exposure to the apop- 
totic stimuli or were cotreated with TLCK or TPCK and dexam- 
ethasone or etoposide for 4 h. In experiments toinvestigate whether the 
TLCK-sensitive target was pre-existing or was synthesised in response 
to apoptotic stimuli, TLCK (100 ,uM) was incubated without cells for 
up to l h in culture medium before dilution with a cell suspension to 
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give a final TLCK concentration of 50/IM and a final cell density of 
2 x 10 7 cells.ml - . These cultures were then further incubated for 4 h 
with either dexamethasone or etoposide. 
2.3. Apoptosis assessed by flow cytometry 
Thymocytes (1 × 106) were stained with Hoechst 33342 and propid- 
ium iodide and viable apoptotic and normal cells separated by flow 
cytometry [10]. The apoptotic ells exhibit a higher blue fluorescence 
due to greater Hoechst 33342 staining and when sorted by flow cytom- 
etry display apoptotic morphology and internucleosomal cleavage [10]. 
All protease inhibitors were used at nontoxic oncentrations a  assessed 
by exclusion of propidium iodide. 
2.4. DNA analysis and cell size 
Cells (5 × 106) were lysed and high molecular weight DNA separated 
from degraded chromatin as described [3]. The amounts of DNA in the 
supernatant (degraded) and the pellet (high molecular weight) were 
quantified using the diphenylamine r action [27]. Conventional and 
field inversion gel electrophoresis (FIGE) were carried out as previously 
described [5,28]. Cell sizing and electron microscopy were carried out 
as described [7,29]. 
3. Results 
3.1. TLCK and TPCK inhibit internucleosomal cleavage of  
DNA and DNA fragmentation 
Control cells showed a small amount of internucleosomal 
cleavage of DNA (Fig. 1, lane 1) consistent with a low level of 
spontaneous apoptosis. Incubation of thymocytes for 4 h with 
dexamethasone (0.1/.tM) or etoposide (10/.tM) caused an in- 
crease in internucleosomal cleavage of DNA (Fig. 1, lanes 2 and 
5, respectively). Both TPCK (25 ¢tM) and TLCK (50 ¢tM) 
caused a marked inhibition of DNA laddering induced by both 
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Fig. 1. Conventional garose gel electrophoresis of DNA from thy- 
mocytes treated with TLCK and TPCK. Cells (2 × 106/well) were 
loaded and electrophoresis carried out as described [28]. Thymocytes 
were incubated for 4 h either alone (lane 1), with dexamethasone (0.1 
/IM) alone (lane 2), or in the presence of TPCK (25 HM) (lane 3), or 
TLCK (50/IM) (lane 4). Thymocytes were also incubated with eto- 
poside (10/~M) alone (lane 5), or in the presence of TPCK (25/IM) (lane 
6) or TLCK (50/tM) (lane 7). The distance migrated by 123 basepair 
marker is indicated. 
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Table l 
Inhibition of dexamethasone and etoposide induced DNA fragmenta- 
tion by TLCK and TPCK 
Treatment % DNA fragmentation 
Control 6.8 _+ 1.6 
Dexamethasone 28.0 _+ 2.4 
Dexamethasone + TLCK 8.6 + 1.8 
Dexamethasone + TPCK 11.0 + 1.5 
Etoposide 39.8 + 3.6 
Etoposide + TLCK 16.3 +_ 2.5 
Etoposide + TPCK 9.3 + 1.4 
TLCK 2.0 + 0.8 
TLCK 9.4 + 1.2 
Cells were incubated for 4 h with either dexamethasone (0.1 /~M) or 
etoposide (10/IM) to induce apoptosis and the ability ofTLCK (50/IM) 
and TPCK (25/IM) to inhibit DNA fragmentation. The data represent 
the mean (+ S.E.M.) of at least 3 experiments. 
dexamethasone (Fig. l, lanes 3 and 4, respectively) and eto- 
poside (Fig. 1, lanes 6 and 7, respectively). TLCK also inhibited 
internucleosomal cleavage induced by staurosporine (1 HM) 
and thapsigargin (0.05 HM) (data not shown). 
DNA fragmentation is quantifiable by measurement of the 
percentage of diphenylamine-reactive material present in the 
supernatant fraction obtained after centrifugation of lysed cells 
[3]. In agreement with previous studies [3,21], both dexam- 
ethasone and etoposide caused an increase in DNA fragmenta- 
tion (Table 1). These increases were abrogated by both TLCK 
and TPCK (Table 1). 
3.2. TLCK inhibits apoptosis detected by flow cytometry 
In agreement with previous results [10,21,29], both dexam- 
ethasone and etoposide caused an increase in apoptotic cells 
(Table 2). Similarly staurosporine and thapsigargin also caused 
an increase in high blue fluorescent cells. The increase from all 
four stimuli was markedly inhibited by TLCK (Table 2). 
3.3. TLCK inhibits the formation of  large kilobasepair f agments 
of DNA 
Following incubation of rat thymocytes with dexamethasone 
or etoposide, a marked increase in the formation of large frag- 
ments of DNA, particularly of 10-50 kbp, was detected by 
F IGE (Fig. 2A, lanes 4 and 6, respectively) compared to control 
cells (Fig. 2A, lane 3). This DNA cleavage was inhibited by 
Table 2 
TLCK inhibits a common effector 
diverse stimuli 
of thymoctye apoptosis induced by 
Treatment % Apoptotic ells 
Control 10.4 _+ 0.3 
Dexamethasone 25.6 + 1.2 
Dexamethasone + TLCK 7.7 + 1.1 
Etoposide 35.7 + 4.3 
Etoposide + TLCK 13.7 + 1.9 
Thapsigargin 39.5 + 2.0 
Thapsigargin +TLCK 16.2 +_ 2.8 
Staurosporine 23.7 _+ 0.7 
Staurosporine + TLCK 15.3 _+ 0.7 
Cells were incubated for 1 h with TLCK (50 HM) and then further 
incubated for 4 h with either dexamethasone (0.1 HM), etoposide (10 
/.tM), thapsigargin (0.05 HM) or staurosporine (1 HM). The percentage 
of apoptotic ells was then assessed by flow cytometry [10]. The data 
represent the mean (+ S.E.M.) of at least 3 experiments. 
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Fig. 2. FIGE of DNA from thymocytes treated with TLCK or TPCK. 
A. Thymocytes were incubated for 4 h either alone (lane 3), with 
dexamethasone (0.1/~M) alone (lane 4) or in the presence of TLCK (50 
pM) (lane 5), with etoposide (10 pM) alone (lane 6) or in the presence 
of TLCK (50 pM) (lane 7) or with TLCK (50 pM) alone (lane 8). 
B. Thymocyes were also incubated for 4 h with TPCK (25/,tM). Size 
markers, 0.1 100 kbp (lane 1) and 245 2200 kbp (lane 2) are shown. 
Agarose plugs containing 1x 10 ~ cells were prepared and electrophore- 
sis carried out as described [5]. 
TLCK (Fig. 2A, lanes 5 and 7, respectively). TLCK alone 
caused a slight decrease in the large fragments (10-50 kbp) 
observed in the control cells (Fig. 2A compare lanes 3 and 8). 
Thapsigargin and staurosporine also caused an increase in the 
formation of large fragments which was inhibited by TLCK 
(data not shown). 
3.4. TLCK inhibits the decrease in cell volume induced by 
dexamethasone and etoposide 
Thymocytes undergoing apoptosis how a marked decrease 
in cell volume [8,9]. Following dexamethasone treatment, a
proportion of the cells shrink, a change which was prevented 
by TLCK (Fig. 3A). Etoposide also caused a loss of cell volume 
that was inhibited by TLCK (data not shown). 
3.5. A TLCK sensitive target was present in thymocytes prior to 
the induction of apoptosis 
Preincubation of media with TLCK (100 pM)  alone demon- 
strated that TLCK became progressively ess effective at inhib- 
iting apoptosis confirming the known instability of TLCK 
above neutral pH (Fig. 4). The length of incubation of TLCK 
with medium alone clearly affected its ability to subsequently 
inhibit DNA fragmentation (Fig. 4). Thus after 1 h preincuba- 
tion, insufficient TLCK remained to exert any inhibitory effect 
on either dexamethasone- or etoposide-induced apoptosis (Fig. 
4). Only when TLCK was preincubated for 15 min or less was 
there sufficient remaining to inhibit dexamethasone- or eto- 
poside-induced DNA fragmentation (Fig. 4) or the appearance 
of apoptotic ells detected by flow cytometry (data not shown). 
In contrast when cells rather than medium were pretreated with 
TLCK for 1 h and subsequently exposed to apoptotic stimuli, 
marked inhibition of apoptosis was observed (Table 2). These 
results suggested that TLCK bound to and inactivated its tar- 
get, a putative protease, which was already present in thy- 
mocytes and which was not synthesised in response to apop- 
totic stimuli. 
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Fig. 3. The effect of TLCK and TPCK on dexamethasone i duced cell 
shrinkage. Thymocytes were incubated for 4 h either alone ( ) or 
in the presence of dexamethasone (0.1 ,uM) (...) and cell volume assessed 
as described in experimental procedures. The volumes of normal and 
apoptotic ells are shown in ft. (A) Thymocytes were also incubated 
with dexamethasone i  the presence of TLCK (50 pM) (- - -). The size 
distribution of cell treated with TLCK alone was identical to that of 
cells treated with dexamethasone plus TLCK and is not shown for 
clarity. (B) The size distribution of cells treated with TPCK (25 pM) 
alone (- - -) was identical to that of cells treated with dexamethasone 
plus TPCK. 
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3.6. TPCK induces changes characteristic of early apoptosis 
The effects of TPCK on large fragment formation were very 
different from those of TLCK. TPCK (25/~M) alone caused an 
increase in large fragments of 10-50 kbp and ~200 kbp (Fig. 2B) 
compared to control cells (Fig. 2A, lane 3), similar to that seen 
when thymocytes were treated with dexamethasone i  the pres- 
ence of zinc [5]. These thymocytes displayed a distinct ultra- 
structure, characterised by condensed chromatin abutting the 
nuclear membrane [29]. Ultrastructural examination of cells 
following 4h incubation with TPCK (25/zM) revealed that most 
thymocytes (80%) showed a very similar morphology (data not 
shown). Several of the cells treated with TPCK showed disinte- 
gration of the nucleolus together with the formation of cyto- 
plasmic vacuoles. Consistent with the cytoplasmic morphology, 
TPCK (25/~M) alone caused a decrease in cell volume in a 
proportion of the cells (Fig. 3B). Incubation of thymocytes for 
4 h with TPCK (25/IM) resulted in the induction of apoptosis 
(22.2% + 2.2, mean + S.E., n=3), as assessed by flow cytom- 
etry, compared to control cells (9.3% + 0.3). These studies dem- 
onstrated that TPCK induced both biochemical and morpho- 
logical changes associated with early nuclear changes of apop- 
tosis without producing internucleosomal cleavage. 
4. Discussion 
4.1. A pre-existing TLCK-sensitive target is a common effector 
of thymocyte apoptosis 
Apoptosis was induced in thymocytes by four stimuli with 
different mechanisms of action (Table 2). TLCK inhibited all 
the characteristic changes of apoptosis induced by these stimuli, 
i.e. both large fragment formation (Fig. 2A) and internucleo- 
somal cleavage (Fig. I) of DNA, cell shrinkage (Fig. 3A) and 
plasma membrane changes (Table 2). Thus a TLCK-sensitive 
target is required at an early stage of thymocyte apoptosis prior 
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Fig. 4. The TLCK sensitive protease isalready present and not synthe- 
sized in response to apoptotic stimuli. TLCK (100/~M) was incubated 
in culture medium for the indicated times before being added to cells 
to a final concentration f 50/IM with either dexamethasone (0.1/~M) 
(D) or etoposide (10/~M) (o) and further incubated for 4 h. Some cells 
were exposed to only dexamethasone (0.1 ,uM) (m) or etoposide (10/zM) 
(o) for 4 h. After this time, DNA fragmentation was measured as 
described (3,27). The amount of DNA fragmentation seen in untreated 
thymocytes i shown by a dotted line. Results are the mean (+ S.E.M.) 
of 3 experiments. 
to both the nuclear and cytoplasmic changes of apoptosis. The 
data obtained following preincubation of media or cells for 
1 h with TLCK (Fig. 4 and Table 2) suggested that the TLCK- 
sensitive target was pre-existing and not synthesised in response 
to apoptotic stimuli. 
As transcription and translation are often required for thy- 
mocyte apoptosis [30], the possibility that TLCK was affecting 
these was examined by comparing its effects to those of cyclo- 
heximide. Apoptosis induced by dexamethasone, etoposide and 
thapsigargin were inhibited by both TLCK and cycloheximide, 
whereas that induced by staurosporine was inhibited only by 
TLCK (data not shown). These data support a model in which 
the apoptotic machinery is pre-existing and staurosporine in- 
duces apoptosis by acting downstream of de novo protein syn- 
thesis. 
4.2. TPCK inhibits DNA laddering but itself induces earl), 
apoptotic hanges 
TPCK exerted markedly different effects compared to 
TLCK. TPCK inhibited internucleosomal cleavage induced by 
dexamethasone and etoposide (Fig. 1) but alone caused the 
formation of large DNA fragments (Fig. 2B). Weaver et al. [15] 
showed that the induction of internucleososmal cleavage of 
DNA by dexamethasone or teniposide but not the formation 
of large fragments in rat thymocytes was prevented by TPCK. 
On ultrastructural examination of TPCK-treated cells, we ob- 
seved both formation of cytoplasmic vacuoles and condensa- 
tion of chromatin into sharply defined clumps abutting the 
nuclear membrane (data not shown). Both the pattern of DNA 
fragmentation a d the morphology are typical of early nuclear 
changes of apoptosis [5,21,29,31,32]. Consistent with the alter- 
ations in cytoplasmic morphology, TPCK alone induced 
shrinkage in a proportion of cells (Fig. 3B). TPCK also in- 
creased the percentage of high blue fluorescent cells reflecting 
an altered membrane permeability [24]. These data demonstrate 
that the effects of TLCK and TPCK are different and that 
TPCK alone induces many of the early changes of apoptosis 
and only inhibits the terminal stages of DNA fragmentation, 
i.e. internucleosomal cleavage and full chromatin condensa- 
tion. 
4.3. A trypsin-like protease is required/k,r early apoptotic 
changes in thymocytes 
In this study no direct evidence of proteolysis i presented. 
However, TLCK and TPCK at the concentrations we have 
used, inhibit intracellular proteolysis [33,34]. Under identical 
conditions, TLCK stabilised cdc-2 kinase activity, consistent 
with an inhibition ofcyclin degradation [35]. While intracellular 
proteases are the most likely targets of these inhibitors, we 
cannot totally exclude the possibility of other cellular targets. 
As TLCK and TPCK both inhibit cysteine proteases [25], it is 
possible that they exert their effects by inhibition of a cysteine 
protease similar to ICE. The known substrate specificity of ICE 
[36] together with a recent report that a TLCK- and TPCK- 
insensitive ICE-like protease isrequired for the nuclear changes 
of apoptosis [37] make it unlikely that the effects described in 
the present study are due to a direct inhibition of an ICE-like 
protease. This was supported by our preliminary studies, which 
showed that three inhibitors of ICE were ineffective at inhibit- 
ing either dexamethasone or etoposide-induced apoptosis (data 
not shown). The cysteine protease calpain has also been impli- 
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cated in thymocyte apoptosis [16]. We cannot exclude the pos- 
sibility that calpain is a target for TLCK or TPCK. However 
the substrate specificity of calpain [38] and the observation that 
a calpain inhibitor, N-acetyl-Leu-Leu-norleucinal, alone causes 
the formation of large DNA fragments (data not shown) sug- 
gest that calpain is not the target. TLCK inhibits trypsin-like 
proteases but does not inhibit chymotrypsin-like proteases. 
Conversely, TPCK inhibits chymotrypsin-like proteases but 
not trypsin-like proteases [39]. Thus the contrast between the 
effects of TLCK and TPCK described here support a role for 
at least two distinct proteases in thymocyte apoptosis. A 
TPCK-sensitive chymotrypsin-like protease is required for the 
terminal changes of apoptosis, i.e. both the internucleosomal 
cleavage of DNA and the complete condensation of the chro- 
matin and a TLCK-sensitive trypsin-like protease is required 
early in the apoptotic process. This TLCK-sensitive protease 
mediates both cytoplasmic and nuclear changes of thymocyte 
apoptosis induced by diverse stimuli. Therefore this protease, 
which is pre-existing and is not synthesised in response to apop- 
totic stimuli, is a common effector of thymocyte apoptosis. 
Acknowledgements: We thank Mr. R. Snowden for help with the flow 
cytometry and Mrs. J. Symons for preparation of the manuscript. 
References 
[1] Arends, M.J. and Wyllie, A.H. (1991) Int. Rev. Exp. Path. 32, 
223 254. 
[2] Compton, M.M. and Cidlowski, J.A. (1992) Trends Endocrinol. 
Metab. 3, 17 23. 
[3] Wyllie, A.H. (1980) Nature 284, 555 556. 
[4] Walker, ER., Smith, C., Youdale, T., Leblanc, J., Whitfield, J.F. 
and Sikorska, M. (1991) Cancer Res. 51, 1078 1085. 
[5] Brown, D.G., Sun, X.-M. and Cohen, G.M. (1993) J. Biol. Chem. 
268, 3037 3039. 
[6] Oberhammer, F., Wilson, J.W., Dive, C., Morris I.D., Hickman, 
J.A., Wakeling, A.E., Walker, P.R. and Sikorska, M. (1993) 
EMBO. J. 12, 3679 3684. 
[7] Cohen, G.M., Sun, X.-M., Fearnhead, H. MacFarlane, M., 
Brown, D.G., Snowden, R.T. and Dinsdale, D. (1994) J. Immunol. 
153, 507 516. 
[8] Thomas, N. and Bell, EA. (1981) Mol. Cell. Endocrinol. 22, 71-- 
84. 
[9] Wyllie, A.H. and Morris, R.G. (1982) Am. J. Pathol. 109, 78-87. 
[10] Sun, X-M., Snowden, R.T., Skilleter, D.N., Dinsdale, D., 
Ormerod, M.G. and Cohen, G.M. (1992) Anal. Biochem. 204, 
351-356. 
[11] Yuan, J., Shaham, S., Ledoux, S., Ellis, H.M. and Horvitz, H.R. 
(1993) Cell 75, 641-652. 
[12] Miura, M., Zhu, H., Rotello, R., Hartweig, E.A. and Yuan, J. 
(1993) Cell 75, 653 660. 
[13] Kumar, S., Kinoshita, M., Noda, M., Copeland, N.G. and 
Jenkins, N.A. (1994) Genes Dev. 8, 1613 1626. 
[14] Bruno, S., Bino, G.D., Lassota, E, Giaretti, W. and Darzynk- 
iewicz, Z. (1992) Leukemia 6, 1113-1120. 
[15] Weaver, V.M., Lach, B., Walker, P.R. and Sikorska, M. (1993) 
Biochem. Cell Biol. 71,488 500. 
[16] Squier, M.K.T., Miller, A.C.K., Malkinson, A.M. and Cohen J.J. 
(1994) J. Cell Physiol. 159, 229-237. 
[17] Kaufmann, S.H. (1989) Cancer Res. 49, 58713~5878. 
[18] Sarin, A., Adams, D.H. and Henkart, EA. (1993) J. Exp. Med. 
178, 1693 1700. 
[19] Shi, L. Kraut, R.P., Aebersold, R. and Greenberg, A.H. (1992) 
J. Exp. Med. 175, 553-566. 
[20] Suffys, P., Beyaert, R., Van Roy, F. and Fiers, W. (1988) Eur. J. 
Biochem. 178, 257 265. 
[21] Sun, X.-M., Snowden, R.T., Dinsdale, D., Ormerod, M.G. and 
Cohen, G.M. (1994) Biochem. Pharmacol. 47, 187-195. 
[22] Jacobson, M.D., Burne, J.F., King, M.P., Miyashita, T., Reed, 
J.C. and Raft', M.C. (1993) Nature 361, 365-368. 
[23] Jiang, S., Chow, S.C., Nicotera, P. and Orrenius, S. (1994) Exp. 
Cell Res. 212, 84-92. 
[24] Ormerod, M.G., Sun, X.-M., Snowden, R.T., Davies, R., 
Fearnhead, H. and Cohen, G.M. (1993) Cytometry 14, 595 602. 
[25] Powers, J.C. and Harper, J.W. (1986) in: Proteinase Inhibitors 
(Barrett and Salvesen, Eds) Elsevier, Amsterdam, pp. 55-151. 
[26] Raffray, M. and Cohen, G.M. (1991) Arch. Toxicol. 65, 135-139. 
[27] Burton, K. (1956) Biochem. J. 62, 315-323. 
[28] Sorenson, C.M., Barry, M.A. and Eastman, A. (1990) J. Natl. 
Cancer Inst. 82, 749. 
[29] Cohen, G.M., Sun, X-M, Snowden, R.T., Dinsdale, D. and 
Skilleter, D.N. (1992) Biochem. J. 286, 331 334. 
[30] Wyllie, A.H., Morris, R.G., Smith, A.L. and Dunlop, D. (1984) 
J. Path. 142, 67-77. 
[3l] Kerr, J.F.R., Searle, J., Harmon, B.V. and Bishop, C.J. (1987) in: 
Perspectives on Mammalian Cell Death. (Potten, C.S., Ed.) Ox- 
ford University Press, pp. 93-128. 
[32] Cohen, G.M., Sun, X.-M., Snowden, R.T., Ormerod, M.G. and 
Dinsdale, D. (1993) J. Immunol. 151,566-574. 
[33] Mellits, K.H., Hay, R.T. and Goodbourn, S. (1993) Nucleic Acids 
Res. 21, 5059 5066. 
[34] Henkel, T., Machleidt, T., Alkalay, I., Kr6uke, M., Ben-Neriah, 
Y. and Baeuerle, EA. (1993) Nature 365, 182 185. 
[35] Norbury, C., MacFarlane, M., Fearnhead, H.O. and Cohen G.M. 
(1994) Biochem. Biophys. Res. Commun. 202, 1400~1406. 
[36] Thornberry, N.A., Bull, H.G., Calaycay, J.R., Chapman, K.T., 
Howard, A.D., Kostura, M.J., Miller, D.K., Molineaux, S.M., 
Weidner, J.R., Aunins, J., Elliston, K.O., Ayala, J.M., Casano, 
F.J., Chin, J., Ding, G.J.-F., Egger, L.A., Gaffney, E.E, Limjuco, 
G., Palyha, O.C., Raju, S.M., Rolando, A.M., Salley, J.P. Yamin, 
T-T., Lee, T.D., Shively, J.E., MacCross, M., Mumford, R.A., 
Schmidt, J.A., and Tocci, M.J. (1992) Nature 356, 768-774. 
[37] Lazebnik, Y.A., Kaufmann, S.H., Desnoyers, S., Poirier, G.G. 
and Earnshaw, W.C. (1994) Nature 371,346-347. 
[38] Sasaki, T., Kikuchi, T., Yumoto, N., Yoshimura, N. and Murachi, 
T. (1984) J. Biol. Chem. 259, 12489-12494. 
[39] Crawford, C. (1990) in: Intracellular Calcium Dependent Proteol- 
ysis (R.L. Mellgren and T. Murachi, Eds.) CRC Press, pp. 75 89. 
